ArticleInternational journal of molecular sciences2022
Radiofrequency Ablation of Indeterminate Thyroid Nodules: The First North American Comparative Analysis.
Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Effect analysis of percutaneous catheter drainage combined with radiofrequency ablation in the treatment of mixed thyroid nodules.Frontiers in endocrinology · 2025Trial
- Mid-Term Outcomes and Outcome Predictors after Radiofrequency Ablation for Indeterminate Thyroid Nodules Following Functional Imaging Screening: A Retrospective Cohort Study.Korean journal of radiology · 2026Article
- Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review.Diagnostics (Basel, Switzerland) · 2025Review
- Cytological Alterations of Benign Thyroid Nodules Following Radiofrequency Ablation.The Laryngoscope · 2025Article
- Assessment of thermal ablation for treating Bethesda IV thyroid nodules: a systematic review and meta-analysis.Thyroid research · 2025Review
- Safety and Feasibility of US-guided Microwave Ablation for the Treatment of Bethesda III Thyroid Nodules with Negative Eight-Gene Panel Mutational Profile.Radiology. Imaging cancer · 2025Article
- Thermal ablation for Bethesda III and IV thyroid nodules: current diagnosis and management.Ultrasonography (Seoul, Korea) · 2024Article
- Treatment outcomes in patients with papillary thyroid cancer undergoing radiofrequency ablation of metastatic lymph nodes.Gland surgery · 2024Article
- Radiofrequency ablation is an effective treatment for Bethesda III thyroid nodules without genetic alterations.European thyroid journal · 2024Article
- A 6-year single-center prospective follow-up study of the efficacy of radiofrequency ablation for thyroid nodules.Frontiers in endocrinology · 2024Article
- Risk factors of recurrent thyroid nodules after radiofrequency ablation.African health sciences · 2023Article
- Article
- Radiofrequency ablation of an intrathyroidal parathyroid adenoma with intraoperative parathyroid hormone monitoring: a case report of a novel technique.Gland surgery · 2023Article
- Modern Surgical Techniques of Thyroidectomy and Advances in the Prevention and Treatment of Perioperative Complications.Cancers · 2023Review
- Hashimoto's Thyroiditis: A Protective Factor against Recurrence in BRAF-Wild Type Differentiated Thyroid Carcinoma.Cancers · 2023Article
- Global scientific trends on thyroid disease in early 21st century: a bibliometric and visualized analysis.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Thyroid nodules can be classified as benign, malignant, or indeterminate, the latter of which make up 10-30% of nodules. Radiofrequency ablation (RFA) has become an attractive and promising therapy for the treatment of benign thyroid nodules. However, few studies have investigated the safety and efficacy of RFA for the management of indeterminate thyroid nodules. In this study, 178 patients with thyroid nodules diagnosed as benign (Bethesda II) or indeterminate (Bethesda III/IV) by preoperative cytopathological analysis were included. Patients in the benign and indeterminate cohorts had similar thyroid nodule volume reduction rates at 65.60% and 64.20%, respectively (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.